Affiliation:
1. Boston University Schools of Medicine and Public Health, Boston, Massachusetts
2. Policy Analysis Inc. (PAI), Brookline, Massachusetts
3. Pfizer Inc., Collegeville, Pennsylvania
4. Boston Medical Center, Boston, Massachusetts
Abstract
Abstract
Background. Although it is widely accepted that adults with immunocompromising conditions are at greatly increased risk of pneumococcal infection, the extent of risk among immunocompetent adults with chronic medical conditions is less certain, particularly in the current era of universal vaccination of children with pneumococcal conjugate vaccines.
Methods. We conducted a retrospective cohort study using data from 3 healthcare claims repositories (2006–2010) to compare rates of pneumococcal disease in immunocompetent adults with chronic medical conditions (“at-risk”) and immunocompromised adults (“high-risk”), with rates in adults without these conditions (“healthy”). Risk profiles and episodes of pneumococcal disease—all-cause pneumonia, pneumococcal pneumonia, and invasive pneumococcal disease (IPD)—were ascertained from diagnosis, procedure, and drug codes.
Results. Rates of all-cause pneumonia among at-risk persons aged 18–49 years, 50–64 years, and ≥65 years were 3.2 (95% confidence interval [CI], 3.1–3.2), 3.1 (95% CI, 3.1–3.1), and 3.0 (95% CI, 3.0–3.0) times the rates in age-matched healthy counterparts, respectively. We idetified rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, and neuromuscular or seizure disorders as additional at-risk conditions for pneumococcal disease. Among persons with at-risk conditions, the rate of all-cause pneumonia substantially increased with the accumulation of concurrent at-risk conditions (risk stacking): among persons 18–49 years, rate ratios increased from 2.5 (95% CI, 2.5–2.5) in those with 1 at-risk condition to 6.2 (95% CI, 6.1–6.3) in those with 2 conditions, and to 15.6 (95% CI, 15.3–16.0) in those with ≥3 conditions. Findings for pneumococcal pneumonia and IPD were similar.
Conclusions. Despite widespread use of pneumococcal conjugate vaccines, rates of pneumonia and IPD remain disproportionately high in adults with at-risk conditions, including those with conditions not currently included in the Advisory Committee on Immunization Practices’ guidelines for prevention and those with multiple at-risk conditions.
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Oncology
Reference20 articles.
1. Update: pneumococcal polysaccharide vaccine usage—United States;Centers for Disease Control and Prevention (CDC);MMWR Morb Mortal Wkly Rep,1984
2. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices;Centers for Disease Control and Prevention (CDC);MMWR Morb Mortal Wkly Rep,1997
3. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23);Centers for Disease Control and Prevention (CDC);MMWR Morb Mortal Wkly Rep,2010
4. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP);Centers for Disease Control and Prevention (CDC);MMWR Morb Mortal Wkly Rep,2012
5. US hospitalizations for pneumonia after a decade of pneumococcal vaccination;Griffin;N Engl J Med,2013